Market news

Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $137.73, according

Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

KYMR advances KT-621 in atopic dermatitis and asthma, with earlier-than-expected AD data and potential phase III plans by mid-2027.

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Kymera Therapeutics' (KYMR) KT-621 could validate its "oral Dupixent" potential, but with a roughly

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

Moby summary of Kymera Therapeutics, Inc.'s Q2 2026 earnings call

Kymera Therapeutics (KYMR) reported a Q2 net loss Wednesday of $0.62 per share, narrower than a loss

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027. Chief Executive Officer

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Kymera International, a leading global developer and manufacturer of advanced specialty materials and high-performance surface coatings, has announced the appointment of Willson Ropp as Chief Executive Officer, effective June 15, 2026.

Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.

This execution under a pre-scheduled Rule 10b5-1 plan follows 172% one-year stock surge.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 10 Best Performing American Stocks in June 2026. On June 30, 2026, BofA raised the firm’s price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) to $125 from $110 and kept a Buy rating on the shares. BofA adjusted its launch timing expectations after Kymera said enrollment in the […]

Kymera Therapeutics now carries an updated fair value estimate of US$123.76, a modest step up from US$119.19 that has drawn attention to how analysts are fine tuning their price targets. Much of the recent commentary links these changes to earlier than expected completion of the BROADEN2 trial, a pulled forward KT-621 readout, and fresh views on how much of that opportunity belongs in Kymera Therapeutics' valuation today. As you read on, you will see how these moving pieces fit together and...